BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 16565744)

  • 1. Therapy for severe refractory acute graft-versus-host disease with basiliximab, a selective interleukin-2 receptor antagonist.
    Funke VA; de Medeiros CR; Setúbal DC; Ruiz J; Bitencourt MA; Bonfim CM; Neto JZ; Pasquini R
    Bone Marrow Transplant; 2006 May; 37(10):961-5. PubMed ID: 16565744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of the interleukin-2 receptor antagonist basiliximab in steroid-refractory acute graft-versus-host disease.
    Schmidt-Hieber M; Fietz T; Knauf W; Uharek L; Hopfenmüller W; Thiel E; Blau IW
    Br J Haematol; 2005 Aug; 130(4):568-74. PubMed ID: 16098072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Basiliximab is well tolerated and effective in the treatment of steroid-refractory acute graft-versus-host disease after allogeneic stem cell transplantation.
    Massenkeil G; Rackwitz S; Genvresse I; Rosen O; Dörken B; Arnold R
    Bone Marrow Transplant; 2002 Dec; 30(12):899-903. PubMed ID: 12476283
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Basiliximab for the treatment of steroid-refractory acute graft-versus-host disease after unmanipulated HLA-mismatched/haploidentical hematopoietic stem cell transplantation.
    Wang JZ; Liu KY; Xu LP; Liu DH; Han W; Chen H; Chen YH; Zhang XH; Zhao T; Wang Y; Huang XJ
    Transplant Proc; 2011 Jun; 43(5):1928-33. PubMed ID: 21693302
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prophylactic effects of interleukin-2 receptor antagonists against graft-versus-host disease following unrelated donor peripheral blood stem cell transplantation.
    Fang J; Hu C; Hong M; Wu Q; You Y; Zhong Z; Li W; Zou P; Hu Y; Xia L
    Biol Blood Marrow Transplant; 2012 May; 18(5):754-62. PubMed ID: 21963619
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Humanized anti-CD25 monoclonal antibody for prophylaxis of graft-vs-host disease (GVHD) in haploidentical bone marrow transplantation without ex vivo T-cell depletion.
    Chen HR; Ji SQ; Wang HX; Yan HM; Zhu L; Liu J; Xue M; Xun CQ
    Exp Hematol; 2003 Nov; 31(11):1019-25. PubMed ID: 14585364
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunological effects in patients with steroid-refractory graft-versus-host disease following treatment with basiliximab, a CD25 monoclonal antibody.
    Chakupurakal G; García-Márquez MA; Shimabukuro-Vornhagen A; Theurich S; Holtick U; Hallek M; Scheid C; von Bergwelt-Baildon M
    Eur J Haematol; 2016 Aug; 97(2):121-7. PubMed ID: 26492560
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Treatment of severe intestinal acute graft-versus-host disease with CD25 monoclonal antibody in haploidentical hematopoietic stem cell transplantation].
    Chen HR; He XP; Yang K; Lou JX; Liu XD; Guo Z; Chen P; Liu B
    Zhonghua Yi Xue Za Zhi; 2010 Oct; 90(38):2693-6. PubMed ID: 21162899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [CD25 monoclonal antibody for GVHD prophylaxis in non-T-cell depleted haploidentical bone marrow transplantation for treatment of childhood leukemia].
    Chen HR; Ji SQ; Yan HM; Wang HX; Liu J; Xue M; Zhu L
    Zhonghua Er Ke Za Zhi; 2004 Apr; 42(4):294-8. PubMed ID: 15157394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Basiliximab versus daclizumab combined with triple immunosuppression in deceased donor renal transplantation: a prospective, randomized study.
    Kandus A; Arnol M; Omahen K; Oblak M; Vidan-Jeras B; Kmetec A; Bren AF
    Transplantation; 2010 Apr; 89(8):1022-7. PubMed ID: 20075788
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blockade of acute grade IV skin and eye graft-versus-host disease by anti-interleukin-2 receptor monoclonal antibody in genoidentical bone marrow transplantation setting.
    Ozşahin H; Tuchschmid P; Lauener R; Waldvogel K; Nadal D; Seger RA
    Turk J Pediatr; 1998; 40(2):231-5. PubMed ID: 9677728
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of steroid-resistant acute graft-versus-host disease with an anti-IL-2-receptor monoclonal antibody (BT 563) in children who received T cell-depleted, partially matched, related bone marrow transplants.
    Herbelin C; Stephan JL; Donadieu J; Le Deist F; Racadot E; Wijdenes J; Fischer A
    Bone Marrow Transplant; 1994 May; 13(5):563-9. PubMed ID: 8054909
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of anti-CD25 monoclonal antibody used in treating steroid-resistant acute graft-versus-host disease following haploidentical bone marrow transplantation].
    Liu J; Wang HX; Duan LN; Yang HM; Xue M; Zhu L; Ding L; Wang ZD
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):160-3. PubMed ID: 19236770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Meta-Analysis of Interleukin-2 Receptor Antagonists as the Treatment for Steroid-Refractory Acute Graft-
    Shen MZ; Li JX; Zhang XH; Xu LP; Wang Y; Liu KY; Huang XJ; Hong SD; Mo XD
    Front Immunol; 2021; 12():749266. PubMed ID: 34621279
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Rabbit antithymocyte globulin versus basiliximab in renal transplantation.
    Brennan DC; Daller JA; Lake KD; Cibrik D; Del Castillo D;
    N Engl J Med; 2006 Nov; 355(19):1967-77. PubMed ID: 17093248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chimeric anti-CD25 monoclonal antibody for treating acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation].
    Wang JZ; Liu KY; Xu LP; Liu DH; Chen YH; Huang XJ
    Zhonghua Nei Ke Za Zhi; 2008 Nov; 47(11):923-5. PubMed ID: 19080235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initial data on basiliximab in critically ill children undergoing heart transplantation.
    Ford KA; Cale CM; Rees PG; Elliott MJ; Burch M
    J Heart Lung Transplant; 2005 Sep; 24(9):1284-8. PubMed ID: 16143246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of severe steroid-refractory graft-versus-host disease with IL-2R alpha chain (CD25) monoclonal antibody].
    Lu J; Xu LP; Huang XJ; Chen H; Zhang YC; Ren HY; Guo NL; Lu DP
    Zhonghua Yi Xue Za Zhi; 2003 Feb; 83(3):216-9. PubMed ID: 12812665
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamic analysis of tofacitinib and basiliximab in kidney allograft recipients.
    Vafadari R; Quaedackers ME; Kho MM; Mol WM; Chan G; Weimar W; Baan CC
    Transplantation; 2012 Sep; 94(5):465-72. PubMed ID: 22960764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myeloablative haploidentical hematopoietic stem cell transplantation using basiliximab for graft-versus-host disease prophylaxis.
    Huang R; Tu S; Deng L; Kang Q; Song C; Li Y
    Hematology; 2015 Jul; 20(6):313-9. PubMed ID: 25321657
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.